Malignant presacral ghrelinoma with longstanding hyperghrelinaemia

  • Ursula G. Falkmer
  • Thomas Gustafsson
  • Ralf Wenzel
  • Nils Wierup
  • Frank Sundler
  • Harshad Kulkarni
  • Richard P. Baum
  • Sture E. Falkmer


Background. A 57-year old man with low-back pain was found to have a 3 3 3 cm presacral neuroendocrine tumour (NET) with widespread metastases, mainly to the skeleton. His neoplastic disease responded well to peptide receptor radionuclide therapy (PRRT) with the radiotagged somatostatin agonist 177Lu-DOTATATE. During almost 10 years he was fit for a normal life. He succumbed to an intraspinal dissemination.

Procedures. A resection of the rectum, with a non-radical excision of the adjacent NET, was made. In addition to computerized tomography (CT), receptor positron emission tomography (PET) with 68Ga-labelled somatostatin analogues was used.

Observations. The NET showed the growth pattern and immunoprofile of a G2 carcinoid. A majority cell population displayed immunoreactivity to ghrelin, exceptionally with co-immunoreactivity to motilin. Somatostatin receptor scintigraphy and 68Ga-DOTATATE PET-CT demonstrated uptake in the metastatic lesions. High serum concentrations of total (desacyl-) ghrelin were found with fluctuations reflecting the severity of the symptoms. In contrast, the concentrations of active (acyl-) ghrelin were consistently low, as were those of chromogranin A (CgA).

Conclusions. Neoplastically transformed ghrelin cells can release large amounts of desacyl-ghrelin, evoking an array of nonspecific clinical symptoms. Despite an early dissemination to the skeleton, a ghrelinoma can be compatible with longevity after adequate radiotherapy.


Download data is not yet available.
How to Cite
Falkmer U. G., Gustafsson T., Wenzel R., Wierup N., Sundler F., Kulkarni H., Baum R. P., & Falkmer S. E. (2015). Malignant presacral ghrelinoma with longstanding hyperghrelinaemia. Upsala Journal of Medical Sciences, 120(4).

Most read articles by the same author(s)